Continued from page 1

Its medical-products division markets and sells ultrasound-imaging devices, chemistry analyzers, biopsy equipment, bone densitometers, robotic surgical machinery and other supplies.

The flat performance of its stock in recent months should not deter investors, Miss Chen said.

“We remain positive on [Chindex International] and view any weaknesses on the stock as a buying opportunity,” she said.

Risks that she said threaten the company’s growth include political conditions and China’s dependence on foreign trade, new medical technology that could disrupt Chindex International’s product line and dependence on dealers to sell the equipment.

The company was founded in 1981 and operates with about 1,000 employees.